|Programm||"Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"|
Evidence-based Indications for PDT outside the TAP and VIP Trial
In the treatment of Age-related Maculadegeneration (AMD) Photodynamic Therapy (PDT) with Verteporfin is established. The two multicenter trials TAP (Treatment of Age-related Maculadegeneration with Photodynamic Therapy) and VIP (Verteporfin in Photodynamic Therapy) show a significant stabilisation of visual function following PDT-treatment compared to a placebo-treated group of patients. These effects are evident for classic and occult choroidal neovascularisations (CNV) of AMD. The therapeutic mechanism of PDT can be used to treat other diseases of the central retina such as Angoid streaks and POHS. In addition choroidal Hemangiomas can be treated by PDT. This contribution discusses indications for PDT-treatment outside the TAP and VIP trials. Recent publications and examples will be demonstrated.